HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $38 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Edward White has reiterated a 'Buy' rating on Syndax Pharmaceuticals (NASDAQ:SNDX) and maintained a price target of $38.
August 04, 2023 | 4:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Syndax Pharmaceuticals has received a reiterated 'Buy' rating from HC Wainwright & Co. with a maintained price target of $38.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates their continued confidence in Syndax Pharmaceuticals. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100